ovarian cancer

Corcept, Clovis Score Wins in Advanced Ovarian Cancer
BioSpace
Thu, 03/31/22 - 10:32 am
Clovis Oncology
Corcept Therapeutics
ovarian cancer
clinical trials
ImmunoGen Ovarian Cancer Drug Reaches BLA Milestone
BioSpace
Tue, 03/29/22 - 11:37 pm
Immunogen
ovarian cancer
FDA
mirvetuximab soravtansine
Verastem takes on debt to get RAS tumor program to finish line
Fierce Biotech
Mon, 03/28/22 - 10:10 am
Verastem
ovarian cancer
non-small cell lung cancer
funding
Immunogen's phase 3 ADC survival data spook investors, sending stock down ahead of FDA filing
Fierce Biotech
Mon, 03/21/22 - 10:17 am
Immunogen
mirvetuximab soravtansine
ovarian cancer
clinical trials
antibody-drug conjugate
Sutro’s folate challenge to Immunogen hits a problem
EP Vantage
Fri, 01/7/22 - 10:29 am
Sutro
STRO-002
ovarian cancer
ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial
Fierce Biotech
Tue, 11/30/21 - 10:29 am
Immunogen
mirvetuximab soravtansine
ovarian cancer
FDA
antibody-drug conjugate
VCs back Leucid to trial CAR-T twist in ovarian cancer patients
Fierce Biotech
Thu, 10/21/21 - 10:40 am
Leucid Bio
CAR-T
ovarian cancer
clinical trials
venture capital
Two More Cancer Drug Candidates Hit the Fast Track
BioSpace
Mon, 08/16/21 - 12:16 pm
ovarian cancer
breast cancer
fast track status
IN10018
InxMed
Carrick Therapeutics
samuraciclib
Clovis spikes ovarian cancer combo after 'underwhelming' efficacy; Servier wins priority review for Tibsovo expansion
Endpoints
Wed, 05/5/21 - 10:42 am
Clovis Oncology
earnings
Lucitanib
Opdivo
Bristol Myers Squibb
ovarian cancer
Anixa Hits FDA Speedbump for Ovarian Cancer CAR-T Trial Approval
BioSpace
Tue, 04/20/21 - 10:56 am
Anixa Biosciences
FDA
CAR-T
ovarian cancer
Mersana starts to lose its shine
EP Vantage
Wed, 01/6/21 - 10:38 am
Mersana
ovarian cancer
XMT-1536
antibody-drug conjugate
Merck and AstraZeneca's Cancer Drug Wins 3 New Approvals in Japan
Motley Fool
Tue, 12/29/20 - 10:57 am
Merck
AstraZeneca
Japan
ovarian cancer
prostate cancer
pancreatic cancer
Lynparza
Aspira adds slate of female execs as it launches new ovarian cancer awareness push
Fierce Pharma
Tue, 11/10/20 - 07:39 pm
Aspira Women's Health
women executives
ovarian cancer
KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor
Fierce Biotech
Sun, 10/25/20 - 11:28 pm
KSQ Therapeutics
PARP inhibitors
ovarian cancer
breast cancer
KSQ-4279
Merck
AstraZeneca
Lynparza
ESMO: Merck and AstraZeneca's 5-Year Lynparza Data in Ovarian Cancer and More
BioSpace
Sun, 09/20/20 - 08:00 pm
ESMO
Merck
AstraZeneca
clinical tirals
Lynparza
ovarian cancer
ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show
Fierce Pharma
Sun, 09/20/20 - 07:44 pm
Merck
Eisai
Keytruda
Lenvima
ovarian cancer
colorectal cancer
VBL’s ovarian cancer drug comes though interim phase 3 review
Fierce Biotech
Thu, 08/13/20 - 09:42 am
VBL Therapeutics
clinical trials
VB-111
ovarian cancer
Genentech's Tecentriq-Avastin Combo Fails to Hit Primary Endpoint in Ovarian Cancer
BioSpace
Mon, 07/13/20 - 12:15 pm
Genentech
Roche
clinical trials
Tecentriq
ovarian cancer
Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer
Pharmaceutical Business Review
Thu, 06/11/20 - 11:16 am
Clovis Oncology
clinical trials
Rubraca
ovarian cancer
Opdivo
Bristol-Myers Squibb
AstraZeneca, Merck's star PARP inhibitor Lynparza expands reach in ovarian cancer with new US approval
Endpoints
Mon, 05/11/20 - 10:40 am
AstraZeneca
Merck
Lynparza
ovarian cancer

Pages